Table 1.
Characteristics of trial participants
| Characteristic | AP | CY | WDL | Total |
|---|---|---|---|---|
| No. randomly assigned | 158 | 166 | 165 | 489 |
| Male gender (n [%]) | 88 (56) | 98 (59) | 93 (56) | |
| Age at transplantation (years; n [%]) | ||||
| <35 | 40 (25) | 50 (30) | 46 (28) | 136 |
| 35 to 44 | 39 (25) | 34 (20) | 37 (22) | 110 |
| 45 to 54 | 38 (24) | 42 (25) | 57 (35) | 137 |
| ≥55 | 41 (26) | 40 (24) | 24 (15) | 105 |
| Years on dialysis (median [range]) | 1.24 (0.20 to 21.70) | 1.16 (0.10 to 11.50) | 1.21 (0.10 to 8.60) | 1.22 (0.00 to 21.70) |
| History of ischemic heart disease (n [%]) | 22 (14) | 29 (17) | 22 (13) | 73 |
| BMI at transplantation (kg/m2; [n]) | ||||
| <25 | 98 (63) | 109 (67) | 112 (70) | 319 |
| ≥25 | 57 (37) | 53 (33) | 47 (30) | 157 |
| Smoking (ever/never; n) | 81/77 | 96/67 | 87/76 | 262/220 |
| Latitude of primary residence (n [%]) | ||||
| >35°Sa | 27 (18) | 26 (16) | 30 (19) | 83 |
| 30 to 35°S | 70 (46) | 77 (48) | 72 (46) | 219 |
| <30°S | 55 (36) | 57 (36) | 56 (35) | 168 |
| Eye color (brown/not brown; n) | 60/98 | 66/99 | 49/114 | 175/311 |
| Skin type (n [%]) | ||||
| fair and freckles | 16 (10) | 10 (6) | 8 (5) | 34 |
| fair, no freckles | 27 (17) | 27 (16) | 24 (15) | 78 |
| olive | 66 (42) | 69 (42) | 78 (48) | 213 |
| darker skin | 49 (31) | 59 (36) | 54 (33) | 162 |
| Previous skin cancer (yes/no; n) | 3/155 | 3/163 | 1/163 | 7/481 |
| Cold ischemia time (hours; median [range]) | 22 (7 to 60) | 22 (4 to 30) | 23 (8 to 39) | 22 (4 to 60) |
| HLA mismatches (n [%]) | ||||
| 0 | 2 (1) | 2 (1) | 1 (1) | 5 |
| 1 to 2 | 52 (33) | 55 (33) | 58 (36) | 165 |
| ≥3 | 102 (65) | 108 (65) | 100 (63) | 310 |
| 2 DR mismatches | 18 (12) | 19 (12) | 20 (13) | 57 |
| PRA (current; n) | ||||
| ≤20% | 132 (89) | 138 (87) | 130 (85) | 400 |
| >20% | 16 (11) | 21 (13) | 23 (15) | 60 |
| Received ATG (n [%]) | 94 (59) | 9 (5) | 8 (5) | 111 |
aIncludes those with predominant residential history of NZ, northern and southern Europe and Pacific Islands.
BMI, body mass index; PRA, panel-reactive antibodies.